Last updated on November 2017

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis


Brief description of study

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis

Detailed Study Description

The primary objective of this study is to evaluate whether SEL can cause fibrosis regression and reduce progression to cirrhosis and associated complications in subjects with NASH and bridging (F3) fibrosis.

The secondary objective of this study is to assess the safety and tolerability of SEL in subjects with NASH and bridging (F3) fibrosis.

Clinical Study Identifier: TX12762

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Columbus Regional Research Institute

Columbus Regional Research Institute
Columbus, GA USA
  Connect »